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Abstract
Objectives—Posttraumatic stress disorder (PTSD) can be a consequence of acute medical events
and has been associated with nonadherence to medications. We tested whether increased concerns
about medications could explain the association between PTSD and nonadherence to medication
in stroke survivors.
Design—We surveyed 535 participants aged 40 years or older who had at least 1 stroke or
transient ischemic attack in the previous 5 years.
Methods—We assessed PTSD using the PTSD checklist–specific for stroke, medication
adherence with the Morisky Medication Adherence Questionnaire, and beliefs about medications
wtih the Beliefs about Medicines Questionnaire. We used logistic regression to test whether
concerns about medications mediated the association between stroke-induced PTSD and
nonadherence to medication. Covariates for adjusted analyses included age, sex, race, comorbid
medical conditions, stroke-related disability, years since last stroke/TIA, and depression.
Results—Symptoms of PTSD were correlated with greater concerns about medications (r= 0.45;
P< .001), and both were associated with medication nonadherence. Adjustment for concerns about
medications attenuated the relationship between PTSD and nonadherence to medication, from an
odds ratio [OR] of 1.04 (95% confidence interval [CI], 1.01–1.06; OR, 1.63 per 1 SD) to an OR of
1.02 (95% CI, 1.00–1.05; OR, 1.32 per 1 SD), and increased concerns about medications remained
associated with increased odds of nonadherence to medication (OR, 1.17; 95% CI, 1.10–1.25; OR,
1.72 per 1 SD) in this fully adjusted model. A bootstrap mediation test suggested that the indirect
effect was statistically significant and explained 38% of the association of PTSD to medication
nonadherence, and the direct effect of PTSD symptoms on medication nonadherence was no
longer significant.
Conclusion—Increased concerns about medications explain a significant proportion of the
association between PTSD symptoms and nonadherence to medication in stroke survivors.
Though posttraumatic stress disorder (PTSD) was originally understood as a disorder
primarily associated with combat, PTSD is increasingly recognized as a common
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psychological consequence of life-threatening medical events such as acute coronary
syndrome (ACS), (Edmondson et al., 2012) cancer diagnosis (Andrykowski, Cordova,
Studts, & Miller, 1998), and stroke (Kronish, Edmondson, Goldfinger, Fei, & Horowitz,
2012). In a meta-analysis of 24 studies, the prevalence of PTSD due to ACS was estimated
at 12% (Edmondson, Richardson, et al., 2012), and research suggests that PTSD due to
stroke may be even more common (Kronish, Edmondson, Goldfinger, et al., 2012). In
addition to directly causing psychological symptoms, PTSD triggered by medical events
may also put patients at increased risk for a worse prognosis from their underlying medical
illness. For example, ACS-induced PTSD is associated with a doubling of risk for cardiac
event recurrence and mortality up to 3 years after the index event (Edmondson, Richardson,
et al., 2012; Edmondson, Rieckmann, et al., 2011; Shemesh et al., 2004; von Känel et al.,
2011). It is not known whether stroke-induced PTSD is associated with adverse medical
outcomes.
While a number of biological mechanisms, such as increased blood pressure (Muraoka,
Carlson, & Chemtob, 1998), endothelial dysfunction (von Känel et al., 2008) and systemic
inflammation (von Kanel et al., 2010) have been proposed to explain the association
between PTSD and recurrent cardiovascular events in ACS patients, behavioral mechanisms
(Newman et al., 2011) such as medication nonadherence are also possible mechanisms
(Rahiman et al., 2008; Shemesh, et al., 2004). In survivors of strokes and transient ischemic
attacks (TIAs), adherence to risk-reducing medications, including antiplatelet agents,
antihypertensive agents, and statins, is especially important for preventing subsequent
strokes (Rothwell, Algra, & Amarenco, 2011). However, in the Adherence eValuation After
Ischemic Stroke Longitudinal (AVAIL) registry, a large prospective cohort of stroke
survivors, 14% of participants self-reported not adhering to medication regimens (Bushnell
et al., 2011). To date, most studies have focused on demographic and system-level
predictors of nonadherence, many of which may be intractable (Bushnell et al., 2010;
Tuhrim et al., 2008). We previously reported that 40% of our sample of predominantly low-
income and minority long-term stroke survivors self-reported poor adherence to medication
and that 75% reported at least some PTSD symptoms, with 18% of the participants reporting
symptoms above the cutoff point for likely PTSD diagnosis. Furthermore, we found that
those with the most severe PTSD symptoms were nearly 3 times as likely as those without
PTSD symptoms to be nonadherent to medications (Kronish, Edmondson, Goldfinger, et al.,
2012).
Social cognitive theories of health behavior such as the health belief model (Rosenstock,
1974) and self-regulation models (Hall & Fong, 2007; Leventhal, Brissette, & Leventhal,
2003; Maes & Gebhardt, 2000) suggest that individuals undertake a cost-benefit analysis
when deciding to follow medical treatment; this process involves considering whether the
perceived need for treatment outweighs concerns about treatment. Though they did not
measure PTSD or other potential influences on concerns about medications, a recent study
with 180 stroke survivors found that concerns about medications were among the strongest
predictors of stroke survivors’ nonadherence to medications both cross-sectionally and
prospectively at 1 year poststroke (O’Carroll et al., 2011).
One hypothesis to explain the association between PTSD and nonadherence to medication is
that stroke survivors with PTSD have increased concerns about medications, potentially
shifting the balance between perceived need and concerns, with the result of decreased
adherence. This explanation is plausible, as 2 major categories of PTSD symptoms—
hypervigilance and avoidance—may lead those with PTSD as a result of a medical event to
perceive their medications as threatening reminders of the event (Shemesh et al., 2001;
Shemesh, et al., 2004). While it is possible that other explanations may play a role in the
association between PTSD and medication nonadherence, such as altered risk perception in
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patients with PTSD (Edmondson, Shaffer, Denton, Shimbo, & Clemow, 2012) or general
avoidance of threatening health-related stimuli (Newman, et al., 2011), the hypervigilance
and avoidance hypothesis is supported by findings on PTSD and medication adherence in
HIV patients (Delahanty, Bogart, & Figler, 2004). Catz et al explained the finding that
symptoms of HIV-induced PTSD were associated with skipping highly active antiretroviral
therapy by noting that the most frequently cited reason for nonadherence to HIV
medications was that “medications remind me that I am HIV positive” (Catz, Kelly, Bogart,
Benotsch, & McAuliffe, 2000; Chernoff, 2007). Evidence for the hypervigilance and
avoidance hypothesis would be a finding that greater concerns about potential threats
associated with medications and greater general worry about medications, but not decreased
awareness that such medications are medically necessary, mediate the association between
PTSD and medication nonadherence. Our aims were to explore the association between
beliefs about medications and PTSD in survivors of strokes and TIAs and to determine
whether beliefs mediated the association we previously found between PTSD and
nonadherence to medication. We hypothesized that greater concerns about medications, but
not lower perceptions of the necessity of medications, mediate the association between
PTSD symptoms and nonadherence to medication in a large sample of stroke survivors.
Methods
Participants
Participants were recruited between March 2010 and January 2012 as part of the Preventing
Recurrence of All Inner City Strokes through Education (PRAISE) clinical trial, which tests
the effectiveness of a peer-led educational workshop at improving risk factor control in
community-dwelling survivors of strokes and TIAs. Participants were eligible for the trial if
they were at least 40 years old and if they self-reported a history of stroke or TIA in the prior
5 years. Participants were excluded if they were not able to provide informed consent, if
they did not speak English or Spanish, if they resided in nursing homes or other
institutionalized settings, if they were pregnant, or if they were unable to meaningfully
participate in the workshop as a result of aphasia or severe cognitive impairment.
Participants were identified through screenings at senior centers, churches, and health fairs;
by contacting patients with a history of stroke or TIA who were on hospital registries of an
academic medical center, a federally funded neighborhood health center, and the Visiting
Nurse Service of New York; and through advertising the study in clinics, local
organizations, and newspapers in northern Manhattan and southern Bronx, New York. The
data used for the analysis were collected as part of the baseline interview for the trial; no
study-related interventions had occurred prior to this baseline interview. All study
procedures were designed with the input of a community action board that included
individuals from East and Central Harlem. Approval was obtained from the institutional
review board of the Mount Sinai School of Medicine, New York, NY. All participants
provided written informed consent. More detail concerning the study’s methods are given
elsewhere (Goldfinger et al., 2012; Kronish, Edmondson, Goldfinger, et al., 2012).
Measures
Symptoms of PTSD and Adherence to Medications—Symptoms of PTSD were
assessed with a modified version of the PTSD checklist–specific (PCL), using the stressor
“stroke or mini-stroke” (Weathers FW, 1993). The PCL is an extensively validated 17-item
scale that corresponds to Diagnostic and Statistical Manual of Mental Disorders (Fourth
Edition) criteria for PTSD. Participants were asked to rate whether they had specific PTSD
symptoms as a result of their stroke or mini-stroke. To make the PCL more homogenous
with the rest of the survey and easier to complete for participants with low health literacy,
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the instrument was modified from a 5-point (“not at all,” “a little bit,” “moderately,” “quite a
bit,” or “extremely”) to a 4-point (“not at all,” “a little bit,” “somewhat,” or “very much”)
response scale. In addition, 3 items (“loss of interest or pleasure in doing things”, “trouble
falling or staying asleep, or sleeping too much,” and “Trouble concentrating on things, such
as reading the newspaper or watching television”) from the Patient Health Questionnaire
(PHQ) (Kroenke, Spitzer, & Williams, 2001) were used in place of PCL items as there was
substantial content and wording overlap between these items on both instruments.
We submitted the revised scale to a confirmatory factor analysis (CFA) to test the
performance of the three altered items. The results of the CFA verified that these 3 PHQ
items performed as predicted, loading on first-order PTSD symptom factors, with
standardized factor loadings equivalent to PCL items. To allow our scoring to be
comparable with that of other studies using the PCL, we recoded PCL scores to reflect the
standard 5-point response scale (1 = 1; 2 = 2.33; 3= 3.67; and 4 = 5) so that the range of the
total PCL score was the same as that used with the unmodified instrument. A cutoff point of
50 on the PCL has corresponded to a sensitivity of 60% and specificity of 99% in relation to
a clinical diagnosis of PTSD in which the triggering event was medical (breast cancer
diagnosis). (Andrykowski, et al., 1998). For illustrative purposes, we divided participants
into two groups based on PCL score, with ≥ 50 representing a positive screen. Concerns
about medications by PTSD group are given in Table 2. The PCL was analyzed as a
continuous variable in regression analyses.
Adherence to medications was measured using the 8-item Morisky Medication Adherence
Questionnaire (Morisky, Ang, Krousel-Wood, & Ward, 2008). This questionnaire is a self-
report measure of adherence that has good internal validity. Each of the 8 items assesses
specific medication-taking behaviors such as forgetting to take medications or stopping
medication use when one perceives one’s medical condition to be under good control.
Summary scores on the questionnaire are concordant with objective measures of adherence
to medication, including pharmacy refills (Krousel-Wood et al., 2009). Though the scale has
been used successfully to assess adherence to a broad range of medications from
antiretrovirals (DiIorio et al., 2008) to asthma medications (Joshi et al., 2006), we asked
participants to respond to the more general “medicines.” To reduce social desirability
effects, the questions related to adherence to medication were preceded by the statement,
“We want to know how you feel, not how you think doctors or other people you know feel.”
According to the cutoff points recommended by the developers of the questionnaire,
participants who scored less than 6 points were categorized as not adherent to medications
and participants who scored 6 to 8 points were categorized as adherent to medications
(Morisky, et al., 2008). Internal reliability (Cronbach α) for the scale in this sample is 0.67.
Beliefs About Medications
Concerns About Medications: Concerns about medications were measured using 4 items
from a modified version of the concerns about medications scale of the Beliefs about
Medicines Questionnaire (BMQ)(Horne, Weinman, & Hankins, 1999). Three items ask
participants to rate the degree to which they worry about “having to take your medicines,”
“long-term effects of your medicines,” and “becoming too dependent on your medicines.”
The fourth item asks how much “medicines disrupt your life.” Based on participant feedback
during pilot testing, we dropped the fifth item, “my medicines are a mystery to me,” and
modified the response scale for each item (1, “not at all,” to 4, “very much”) to make it more
similar to the rest of the survey and to simplify the responses for stroke survivors who may
have cognitive impairment. The 4 items were summed for a total concerns score. Internal
consistency reliability (Cronbach α) for the 4-item scale in this sample was 0.71.
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Necessity of Medications: Beliefs about the necessity of medications were assessed using a
modified version of the 5-item necessity scale of the BMQ. The 5 items ask participants to
rate the degree to which “your health depends on your medications,” they would be “ill
without your medications,” “your health in the future depends on your medications,” “your
life would be impossible without your medications,” and “your medicines protect you from
becoming worse.” The response scale for each item ranged from 1, “not at all,” to 4, “very
much,” and the 5 items were summed for a total necessity score. Internal consistency
reliability (Cronbach α) for the scale in this sample was 0.80.
General Harm and Overuse of Medications: Beliefs that medications are generally
harmful or generally overused by physicians were measured with items adapted from the
general harm and general overuse scales of the BMQ. Items on the general harm scale ask
participants to rate the degree to which medicines are generally harmful (eg, how much do
you agree with the following statement: natural remedies are safer than medicines). Items on
the general overuse scale ask participants to rate the degree to which physicians overuse
medicines (eg, how much do you agree with the following statement: doctors place too
much trust in medicines). The response scale for each item ranged from 1, “not at all,” to 4,
“very much,” and the items for each scale were summed for a total score. Internal
consistency reliability (Cronbach α) for the 4-item general harm scale in this sample was
0.65 and for the 4-item general overuse scale was 0.64.
Depression symptoms were measured using the 8-item PHQ (PHQ-8). The PHQ-8 has
discriminant properties for diagnosing depression similar to those of the 9-item version,
(Kroenke, Spitzer, Williams, & Lowe, 2010) and the 9-item version has been validated for
use in patients after stroke (Schmid et al., 2011) and in minority populations (Huang, Chung,
Kroenke, Delucchi, & Spitzer, 2006). A score of 10 or higher on the PHQ-8 signifies at least
mild to moderate depressive symptoms.
Demographic information, including age, sex, race/ethnicity, annual household income, and
insurance status, was also collected by patient interview. For cases when data was missing
on annual household income (n=40), participants were categorized as having “low income”
if they had Medicaid insurance. Three participants were missing information on both income
and insurance status and were not included in the adjusted logistic regression models.
Stroke severity was measured using the modified Rankin Scale (Wilson et al., 2002); a score
of 3 or higher on this scale signifies at least moderate disability as a result of the stroke.
Time since stroke was measured by asking the year of their most recent stroke or TIA
(Banks & Marotta, 2007). Number and severity of medical comorbid conditions was
measured using the Charlson comorbidity index (Charlson, Pompei, Ales, & MacKenzie,
1987).
Analysis Plan
We tested the hypothesis that concerns about medications significantly mediate the
relationship between PTSD symptoms and increased likelihood of nonadherence to
medication in 3 steps, based on recommendations by MacKinnon and Dwyer (MacKinnon &
Dwyer, 1993) for testing mediation with dichotomous outcomes. First, using linear
regression, we estimated the association of PTSD with concerns about medications. Then,
using hierarchical logistic regression, we assessed the unadjusted and adjusted associations
(95% confidence intervals [CIs]) between PTSD and beliefs about medications and between
PTSD and nonadherence to medications. Finally, we tested whether the adjusted relationship
between PTSD symptoms and nonadherence to medication was significantly attenuated after
adjustment for beliefs about medications. We chose covariates for adjusted analyses based
on a review of the literature for important patient-level predictors of poor adherence to
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cardiovascular medications (Mann, Woodward, Muntner, Falzon, & Kronish, 2010;
Osterberg & Blaschke, 2005). Covariates included age, sex, African American race, time
since stroke, severity of stroke disability, number and severity of medical comorbid
conditions, and depression symptoms.
We used a new SPSS macro (Hayes, 2012) that calculates total, direct, and indirect effects
(total and specific for each mediator), including tests of significance using bootstrap
procedures, which do not assume normality of the distribution of the indirect effects and
hence provide stronger protection against type 2 error, compared to normal procedures such
as the Sobel test. We report results for the bootstrap test, with a resample procedure of 5,000
bootstrap samples (bias corrected and accelerated estimates and 95% CI). Finally, effect
ratios were calculated to express the amount of the total effect that is explained by the (total)
indirect effects via the mediators. Effect ratios are a preferable (quantitative) way to describe
mediated effects, compared to the more common dichotomy of “full” vs. “partial”
definitions. For example, an effect ratio of 0.5 would mean that half of the total effects of
the independent on the dependent variable is explained by the mediator, assuming no
suppressing variables are present in the model (Shrout & Bolger, 2002). For illustrative
purposes, we report both the odds ratio associated with a 1 point increase on the PCL and
BMQ, and for a 1 standard deviation increase on those measures.
Results
Participants
We surveyed 535 participants for this study. The mean age of participants was 63 years;
59% were women, 80% were black or Latino; 30% never completed high school; and 56%
earned less than $15,000 yearly (Table 1). The sample and recruitment strategy has been
described in greater detail previously (Goldfinger, et al., 2012; Kronish, Edmondson,
Goldfinger, et al., 2012). PTSD symptom scores were elevated (mean [SD] score, 34.42
[13.71]) and positively skewed (range, 17–80). Eighteen percent of participants had
symptoms consistent with a diagnosis of PTSD (PCL-S score > 50), and 56% of participants
had possible PTSD (PCL-S score, 25–50). Forty-one percent of participants were not
adherent to medications according to the Morisky Medication Adherence Questionnaire.
Compared with participants without PTSD, nearly twice as many participants with likely
PTSD were not adherent (33% vs 65%, P<.001).
Relationship Between PTSD Symptoms and Beliefs About Medications
Responses to individual BMQ items are given in Table 2. Concerns about medications were
prevalent (mean [SD] score, 7.7 [3.5]); the mean response to questions about concerns was
“a little bit.” Symptoms of PTSD were moderately positively correlated with concerns about
medications (r= .45, P< .001).
Beliefs in the necessity of medications were strong (mean [SD] score, 16.7 [3.7]); the mean
response to items on the necessity scale was between “somewhat” and “very much.”
Symptoms of PTSD were weakly positively correlated with greater belief in the necessity of
medications (r= .11, P= .03). Beliefs in the general harm of medications were moderate
(mean [SD] score, 7.56 [2.94]); the mean response to general harm items was “a little bit.”
Symptoms of PTSD were positively correlated with greater belief in the harm of
medications (r= .19, P< .001). Beliefs in the general overuse of medications were
moderate(mean [SD] score, 8.85 [3.16]); the mean response to items on the general overuse
scale was “a little bit.” Symptoms of PTSD were positively correlated with greater belief in
the overuse of medications (r= .22, P< .001).
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Results of logistic regression analyses are given in Table 3. In step 1, two unadjusted logistic
regression analyses showed that both PTSD symptoms (odds ratio [OR], 1.05; 95% CI,
1.03–1.06) and concerns about medications (OR, 1.24; 95% CI, 1.18–1.31) were
significantly related to increased odds of medication nonadherence. In step 2, after adjusting
for demographic, clinical, and depression variables, PTSD symptoms remained significantly
related to increased odds of nonadherence to medication (OR, 1.04; 95% CI, 1.01–1.06; ie,
OR, 1.63 per 1 SD). However, in step 3, adjustment for concerns about medications
attenuated the relationship of PTSD to nonadherence to medication (OR, 1.02; 95% CI,
1.00–1.05; ie, OR, 1.32 per 1 SD). Concerns about medications remained significantly
related to increased odds of nonadherence to medication (OR, 1.17; 95% CI, 1.10–1.25; ie,
OR, 1.72 per 1 SD).
Bootstrap tests of total, direct, and indirect effects
In the bootstrap test for mediation, after adjustment for all covariates, the total (direct and
indirect) effect of PTSD symptoms on odds of nonadherence was b= .035, p=.003, OR=
1.04 per 1 point (OR= 1.61 per SD) increase on the PCL. The direct effect of PTSD
symptoms on odds of nonadherence was b= .023, p= .06, OR= 1.02 per 1 point (OR=1.38
per SD) increase on the PCL. The indirect effect of PTSD symptoms on odds of
nonadherence through increased BMQ concerns was b= .013 (95% CI= .006–.023), which
corresponds to an effect ratio of .38. Thus, 38% of the total effect of PTSD symptoms on
odds of nonadherence was explained by the mediated effect through increased BMQ
concerns. Further, the direct effect of PTSD symptoms on odds of nonadherence was no
longer significant, suggesting mediation.
Sensitivity Analyses
To test whether PTSD’s relationship to nonadherence to medication was due to specifically
cognitive-affective concerns rather than a more general altered belief about the medical
necessity of medications to offset the risk of future adverse medical events, we conducted
the same statistical tests as above with the necessity scale of the BMQ in place of the
concerns scale. Scores on the necessity scale were unrelated to nonadherence to medication
(unadjusted OR, 0.98; 95% CI, 0.93–1.03), and therefore we did not test for mediation. In a
post hoc test, we created a variable to represent the discrepancy between participants’
perception of the necessity of medications and their concerns about medications and tested it
as a mediator of the association of PTSD symptoms to nonadherence. The results were
essentially the same as those for the mediation test conducted on BMQ concerns alone.
We conducted another sensitivity analysis to determine whether the mediated effect was due
specifically to concerns about medications rather than general negative beliefs about
medications, we included all the BMQ scales in the fully adjusted logistic regression model.
As in the primary analysis, the association between PTSD and nonadherence to medication
remained attenuated (OR, 1.01; 95% CI, 0.98–1.04), and concerns about medications
remained significantly associated with nonadherence to medication (OR, 1.15; 95% CI,
1.06–1.25). None of the other BMQ scales were significantly associated with nonadherence
to medication (ORs, 0.96–1.07; P values, .19–.73).
Finally, since PTSD may be particularly associated with skipping medications rather than
merely forgetting medications in some patient populations (Kronish, Edmondson, Li, &
Cohen, 2012), we conducted a sensitivity analysis to determine whether the association of
PTSD to medication nonadherence was due to participants forgetting their medications or
intentionally skipping their medications by conducting analyses identical to the primary
mediation analysis except that single Morisky items concerning forgetting or skipping
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medications were analyzed as the dependent variable. Unlike Kronish et al. (2012), we
found no differential associations by type of nonadherence.
Discussion
Researchers have reported that psychological distress in the form of PTSD symptoms is
prevalent after life-threatening medical events (Edmondson, Richardson, et al., 2012), that
PTSD due to such events may increase patients’ risk for future medical events (Edmondson,
Rieckmann, et al., 2011), and that PTSD is related to nonadherence to medication after those
events (Kronish, Edmondson, Goldfinger, et al., 2012). However, the mechanisms for the
association between PTSD and nonadherence have not been previously investigated. In a
large sample of stroke survivors, we found that 38% of the risk for nonadherence to
medication associated with PTSD was accounted for by concurrent increased concerns about
medications. PTSD was also associated with somewhat increased beliefs in the general harm
and overuse of medications in the medical system; however, these beliefs were not
associated with nonadherence and did not account for the association between PTSD and
nonadherence. Finally, although PTSD symptoms were related to slightly stronger beliefs in
the necessity of medications, the perceived necessity of medications did not appear to affect
adherence to medication in stroke survivors with PTSD.
In this study, compared with patients without PTSD after stroke, patients with PTSD had
increased ambivalence toward medications. Although we did not directly measure the
degree to which medications reminded patients of their stroke, this finding is consistent with
our hypothesis that medications may serve as particularly potent reminders of trauma in
stroke survivors with the hypervigilance and avoidance symptoms of PTSD (Catz, et al.,
2000; Chernoff, 2007). However, future research should directly test the extent to which
medications serve as reminders of the event before strong conclusions can be drawn.
Experimental and observational research has shown that PTSD symptoms are related to
increased psychological susceptibility to both conscious and unconscious reminders of
mortality and that those reminders of mortality are related to predictable behavioral
responses (Abdollahi, Pyszczynski, Maxfield, & Luszczynska, 2011; Edmondson, Chaudoir,
et al., 2011; Kesebir, Luszczynska, Pyszczynski, & Benight, 2011; Park, Edmondson, Hale-
Smith, & Blank, 2009; Pyszczynski & Kesebir, 2011). Though others have hypothesized
that avoiding reminders of the life-threatening medical event might account for the
association between PTSD and nonadherence to medication in survivors of ACS (Shemesh,
et al., 2001), no prior study has tested any potential mediator of the association.
Limitations
This study should be interpreted with its limitations in mind. First, due to the nature of the
parent study, we relied on participants’ self-report of stroke for inclusion in the study, and
we were limited to self-report measures rather than a clinical diagnosis of PTSD or objective
measurement of adherence to medication. Furthermore, adherence to medication and beliefs
about medications were measured with reference to “medicines,” and we cannot know the
extent to which participants responded to questions with reference to their stroke
medications or to other types of medications. Similarly, some of the measures used in the
study evinced somewhat low internal consistency reliability. Future studies of the
association between PTSD triggered by medical events and adherence to medication should
incorporate gold standard measures of both PTSD and adherence to medication and should
assess more directly whether stroke medications act as traumatic reminders of the stroke.
Qualitative and implicit assessment tools such as the Implicit Attitudes Test are promising
approaches for elucidating these likely complex associations. (Chambers et al., 2011;
Greenwald, McGhee, & Schwartz, 1998).
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Also, it is possible that a third variable, such as general neuroticism, could influence both
the development of PTSD and increased concerns about medication after stroke. Other
simplifications of the model, such as the exclusion of medication type and side effects,
polypharmacy, perceived racism, and other barriers to adherence in stroke survivors (Ellis,
2012) may also be a limitation, though their exclusion was in the service of focusing on the
specific mechanism by which PTSD was associated with nonadherence. Future research
should consider including such variables. Future research should also consider the
independent effects of the three PTSD symptom clusters (reexperiencing, avoidance, and
hyperarousal) on nonadherence, as some research suggests that the different clusters may
carry independent recurrent cardiovascular risk after acute cardiovascular events
(Edmondson, Rieckmann, et al., 2011). Finally, because of our study design, geographic
location (Harlem and South Bronx, New York), and population of interest, our participants
were primarily members of racial and ethnic minority groups and had low socioeconomic
status. As such, their beliefs about medications may not be representative of those of other
groups, and they may have distinct associations with PTSD and nonadherence to
medication.
Conclusions
Nonadherence to medication is a major problem in stroke survivors, given that adherence to
medications is the most important component of secondary risk reduction in these patients.
This study is the first to demonstrate that concerns about medications account for a
significant proportion of the relationship between PTSD and nonadherence to medication in
stroke survivors. The results of this study suggest that concerns about medications should be
assessed alongside PTSD symptoms in stroke patients in order to better understand potential
sources of nonadherence.
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Age, y, mean ± SD 63.0 ± 11.3
Women 317 (59)
Race/ethnicity
 Black 210 (40)
 Hispanic 212 (40)
 White 76 (14)
 Other 27 (5)
Income ≤ $15,000/y 300 (56)
Less than high-school education 157 (30)
Preferred language Spanish 127 (24)
Married/live with a partner 192 (36)
Live alone 185 (35)
Employment status
 Full or part time 76 (14)
 Unable to work 205 (38)
 Retired, in school, or other 252 (47)
No. of prior strokes and TIAs, mean ± SD 1.7 ± 1.2
Time since last stroke or TIA, y, mean ± SD 1.9 ± 1.4
Charlson comorbidity index score, mean ± SD 3.7 ± 2.2
Stroke impact severity (modified Rankin Scale score)
 0–2 287 (54)
 3 or 4 248 (46)
Depressed (PHQ-8 score ≥10) 159 (30)
Concerns about medications (mean ± SD BMQ score) 11.2 ± 3.6
Nonadherent to medications (Morisky score, 0–5) 218 (41)
Abbreviations: BMQ, Beliefs about Medicines Questionnaire; PCL-S, PTSD checklist (specific); PHQ-8, 8-item Patient Health Questionnaire;
PTSD, posttraumatic stress disorder; TIA, transient ischemic attack.
a
Data are presented as number (%) unless otherwise specified.
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Table 2
Participants Who Responded “Somewhat” or “Very Much” to BMQ, by PTSD Statusa
No. (%)
Belief Overall (N=535) PTSD (n= 95) No PTSD (n= 440)
Concerns
How much does having to take your medicines worry you?b 136 (26) 48 (52) 88 (20)
How much do you worry about the long-term effects of your medicines?b 182 (35) 56 (62) 126 (29)
How much do medicines disrupt your life?b 89 (17) 40 (45) 49 (11)
How much do you worry about becoming too dependent on your medicines?b 152 (29) 50 (54) 102 (23)
Necessity
How much does your health depend on your medicines?b 471 (88) 91 (96) 380 (86)
Would your life be impossible without your medicines?b 275 (58) 65 (77) 210 (54)
How ill would you be without your medicines?b 340 (74) 71 (85) 269 (72)
How much do you think your health in the future will depend on your medicines? 402 (82) 69 (81) 333 (82)
How much do your medicines protect you from becoming worse? 413 (83) 73 (84) 340 (83)
Abbreviation: BMQ, Beliefs about Medicines Questionnaire.
a
Sample size varies slightly across items due to missing data.
b
P < .05.
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Table 3
Logistic Regression Models Predicting Nonadherence to Medications from PTSD, Demographic and Clinical
Covariates, and Medication Concernsa
Characteristic Model 1 (N=535) Model 2 (N=532) Model 3 (N=532)
PTSD 1.05 (1.03–1.06) 1.04 (1.01–1.06) 1.02 (1.00–1.05)
Age … 0.98 (0.96–1.00) 0.98 (0.96–1.00)
Female … 1.28 (0.86–1.92) 1.26 (0.84–1.90)
Black or African American … 0.80 (0.55–1.15) 0.85 (0.59–1.24)
Income <$15,000/y … 1.01 (0.67–1.52) 1.00 (0.66–1.52)
Charlson comorbidity index score … 1.09 (0.99–1.19) 1.07 (0.98–1.18)
Stroke impact severity (Rankin Scale score) … 0.97 (0.84–1.13) 0.95 (0.82–1.18)
Years since last stroke/TIA … 1.17 (1.02–1.33) 1.17 (1.02–1.34)
Depressive symptoms (PHQ-8 score ≥10) … 1.02 (0.97–1.08) 1.02 (0.97–1.08)
Medication concerns (BMQ score) … … 1.17 (1.10–1.25)
Abbreviations: BMQ, Brief Medication Questionnaire; PCL-S, PTSD checklist (specific); PHQ-8, 8-item Patient Health Questionnaire; PTSD,
posttraumatic stress disorder; TIA, transient ischemic attack.
a
Data are presented as odds ratio (95% confidence interval). Ellipses indicate not applicable.
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